Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Research shows strides in multiplex genotyping technology development
June 9th, 2005
Research presented at the Clinical Virology Symposium demonstrated the sensitivity and technical feasibility of genotyping chemistry now being developed by Digene Corp. (DIGE) as part of its next-generation molecular-testing system, according to the company. Building on the company's Hybrid Capture molecular-testing technology, Digene's new systems are being developed for simultaneous detection of multiple infectious agents and for genotyping of high-risk types of the human papillomavirus (HPV), the cause of virtually all cases of cervical cancer. Recent studies indicate that several specific high-risk HPV types, such as types 16, 18, and 45, are...
Source: Women's Health Weekly (2005-06-09)
|
